Bioniche files for offering in Canada

Bioniche Life Sciences (TSX:BNC) has filed a final short-form prospectus in all provinces of Canada for the sale of 10 million new common shares at a price of $1.45 each. The filing represents the Canadian portion of two concurrent financings, totalling 20 million shares in Canada and an initial public offering in Australia and New Zealand. In [...]

Bioniche to market horse breeding drug in U.S.

Bioniche Life Sciences (TSX:BNC) has signed an agreement with CreoSalus for exclusive rights to market and distribute its SucroMate Equine product in the U.S., with a first right to expand the territory. SucroMate Equine was recently registered by the FDA as a controlled release injectable of deslorelin acetate, used to time ovulation in horses and [...]

Bioniche and Trophogen in license pact

Bioniche Life Sciences (TSX: BNC) has signed an exclusive veterinary license agreement with closely held Trophogen of Rockville, MD that gives Bioniche commercial access to a patented, proprietary superagonist hormone technology platform developed by Trophogen and originally licensed from the National Institutes of Health. The technology will initially be developed into a next-generation follicle stimulating [...]

Riding the Next Wave

No, we’re not talking about the north coast of Maui but rather a new research platform from long-time biotech analyst David Martin of Dundee Securities. “If I’m going to recommend that investors own a basket of biotech stocks, it makes sense that I ought to initiate on a basket of stocks rather than make one-off [...]